Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Nadia Dandachi"'
Autor:
Nadia Dandachi, Marija Balic
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104385- (2022)
Externí odkaz:
https://doaj.org/article/bbcb9ed082d84b36a0e358b12d544b13
Autor:
Noemi Laprovitera, Mattia Riefolo, Elisa Porcellini, Giorgio Durante, Ingrid Garajova, Francesco Vasuri, Ariane Aigelsreiter, Nadia Dandachi, Giuseppe Benvenuto, Federico Agostinis, Silvia Sabbioni, Ioana Berindan Neagoe, Chiara Romualdi, Andrea Ardizzoni, Davide Trerè, Martin Pichler, Antonietta D'Errico, Manuela Ferracin
Publikováno v:
Molecular Oncology, Vol 15, Iss 10, Pp 2732-2751 (2021)
Metastasis is responsible for the majority of cancer‐related deaths. Particularly, challenging is the management of metastatic cancer of unknown primary site (CUP), whose tissue of origin (TOO) remains undetermined even after extensive investigatio
Externí odkaz:
https://doaj.org/article/424ff11210464919aa307fab5d15bc99
Autor:
Nadia Dandachi, Florian Posch, Ricarda Graf, Christoph Suppan, Eva Valentina Klocker, Hannah Deborah Müller, Jörg Lindenmann, Angelika Terbuch, Ellen Heitzer, Marija Balic
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2390-2400 (2021)
Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR+HER2− metastatic breast cancer patients. Biomarkers are urgently needed, and longitudinal biomarker m
Externí odkaz:
https://doaj.org/article/117d480dafe543e89c6b08c0fd35a25b
Autor:
Harry J M Groen, Qing Zhou, Ellen Heitzer, Michael R Speicher, Ed Schuuring, Samantha O Perakis, Sabrina Weber, Ricarda Graf, Sabine Hojas, Jakob M Riedl, Armin Gerger, Nadia Dandachi, Marija Balic, Gerald Hoefler, Jochen B Geigl
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Objective Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a f
Externí odkaz:
https://doaj.org/article/98ddadfdad874cbf99c15c5ec5afd03d
Autor:
Verena Tiran, Stefanie Stanzer, Ellen Heitzer, Michael Meilinger, Christopher Rossmann, Sigurd Lax, Oleksiy Tsybrovskyy, Nadia Dandachi, Marija Balic
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0175223 (2017)
A common symptom during late stage breast cancer disease is pleural effusion, which is related to poor prognosis. Malignant cells can be detected in pleural effusions indicating metastatic spread from the primary tumor site. Pleural effusions have be
Externí odkaz:
https://doaj.org/article/dab9aee4402c43888242fe7455814733
Autor:
Daria Štefatić, Monika Riederer, Marija Balić, Nadia Dandachi, Stefanie Stanzer, Birgit Janesch, Margit Resel, Darko Ler, Hellmut Samonigg, Thomas Bauernhofer
Publikováno v:
Biomolecules & Biomedicine, Vol 8, Iss 3 (2008)
Colorectal cancer is one of the most common cancer types worldwide and it continues to be a serious public health problem. Early detection and diagnosis are of great importance in cancer management. At present, diagnostic blood tests are based on the
Externí odkaz:
https://doaj.org/article/930e2e7731fe44c1b179f4ef6649ef9e
Autor:
Ellen Heitzer, Marija Balic, Michael Gnant, Martin Filipits, Nadia Dandachi, Sabrina Weber, Ricarda Graf, Anders Ståhlberg, Margaretha Rudas, Christian Fesl, Zsuzsanna Bago-Horvath, Peter C. Dubsky, Edgar Petru, Angelika Pichler, Viktor Wette, Rupert Bartsch, Georg Pfeiler, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Sophie Frantal, Simon P. Gampenrieder, Qing Zhou
Purpose:Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, a minimally invasive assessment of tumor response based on cell-free circulating tumor DNA (ctDNA) may be beneficial to guide trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ed243da79c1c37626cfbc7ae763edc
https://doi.org/10.1158/1078-0432.c.6532496
https://doi.org/10.1158/1078-0432.c.6532496
Autor:
Ellen Heitzer, Marija Balic, Michael Gnant, Martin Filipits, Nadia Dandachi, Sabrina Weber, Ricarda Graf, Anders Ståhlberg, Margaretha Rudas, Christian Fesl, Zsuzsanna Bago-Horvath, Peter C. Dubsky, Edgar Petru, Angelika Pichler, Viktor Wette, Rupert Bartsch, Georg Pfeiler, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Sophie Frantal, Simon P. Gampenrieder, Qing Zhou
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bc36db6ecc63d35820191d0eb5f100
https://doi.org/10.1158/1078-0432.22487330
https://doi.org/10.1158/1078-0432.22487330
Autor:
Ellen Heitzer, Marija Balic, Michael Gnant, Martin Filipits, Nadia Dandachi, Sabrina Weber, Ricarda Graf, Anders Ståhlberg, Margaretha Rudas, Christian Fesl, Zsuzsanna Bago-Horvath, Peter C. Dubsky, Edgar Petru, Angelika Pichler, Viktor Wette, Rupert Bartsch, Georg Pfeiler, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Sophie Frantal, Simon P. Gampenrieder, Qing Zhou
Supplementary Table from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e466503ce14d784db53d6e97b43b5c0
https://doi.org/10.1158/1078-0432.22487306
https://doi.org/10.1158/1078-0432.22487306
Autor:
Zsuzsanna Bago-Horvath, Anders Ståhlberg, Christian F. Singer, Michael Gnant, Georg Pfeiler, Marija Balic, Christian Fesl, Edgar Petru, Nadia Dandachi, Sophie Frantal, Gabriel Rinnerthaler, Daniel Egle, Martin Filipits, Ellen Heitzer, Ricarda Graf, Simon Peter Gampenrieder, Viktor Wette, Sabrina Weber, Rupert Bartsch, Margaretha Rudas, Peter Dubsky, Angelika Pichler, Qing Zhou
Publikováno v:
Clinical Cancer Research. 28:697-707
Purpose: Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, a minimally invasive assessment of tumor response based on cell-free circulating tumor DNA (ctDNA) may be beneficial to guide tre